Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India

Novartis

Status: Completed

Conditions: Heart Failure

Treatments: Drug: sacubitril/valsartan

Study type: Observational

Funder types: Industry

Identifiers

NCT04735354

CLCZ696BIN01

Details and patient eligibility

About

This was a non-interventional, retrospective EMR analysis of longitudinal prescriptions in India for a period of 1.5 years. Demographic profile of patients with heart failure with reduced ejection fraction on sacubitril/valsartan was recorded.

Full description

Index date was date of 1st prescription of sacubitril/valsartan. Dose titration of sacubitril/valsartan was assessed for a period of 6 months post index date.

Enrollment: 268 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients ≥18 years with a diagnosis of HFrEF as mentioned in database or heart failure with a recording of LVEF <40% at or before the index date
• A prescription of sacubitril/valsartan

Exclusion criteria

• Diagnosis of HF specified as preserved/mid-range ejection fraction

Trial design

268 participants in 1 patient group

sacubitril/valsartan

Description:

Patients administered sacubitril/valsartan by prescription

Treatment:

Drug: sacubitril/valsartan